Xeroderma pigmentosum variant: response to etretinate.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 2337522.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report a case of the variant form of xeroderma pigmentosum in whom tumour development was completely suppressed for 22 months by etretinate 25 mg daily.
Medical subject headings
- Etretinate
- Skin Neoplasms
- Xeroderma Pigmentosum